Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sanara MedTechSMTI +0.24%74 Return-on-Tangible-Asset is 3.73% as of Mar. 2026. GuruFocus rates SMTI with a GF Score™ of 74/100 and a GF Value™ of $45.87 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 855 Medical Devices & Instruments companies, Sanara MedTech ranks worse than 85.73% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Sanara MedTech's annualizedNet Income for the quarter that ended in Mar. 2026 was $1.8 Mil. Sanara MedTech's average total tangible assets for the quarter that ended in Mar. 2026 was $49.3 Mil. Therefore, Sanara MedTech's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 3.73%.
The historical rank and industry rank for Sanara MedTech's Return-on-Tangible-Asset or its related term are showing as below:
SMTI'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -67.25 Med: -29.56 Max: 16.02
Current: -67.2
During the past 13 years, Sanara MedTech's highest Return-on-Tangible-Asset was 16.02%. The lowest was -67.25%. And the median was -29.56%.
SMTI's Return-on-Tangible-Asset is ranked worse than 85.73% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: 0.62
vs SMTI: -67.20
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Sanara MedTech Return-on-Tangible-Asset Related Terms
Sanara MedTech Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Sanara MedTech's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SMTI vs EMBC, KRMD, UTMD: Return-on-Tangible-Asset Comparison
For the Medical Instruments & Supplies subindustry, Sanara MedTech's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanara MedTech Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sanara MedTech's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Sanara MedTech's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 3.73% mean?
Sanara MedTech (SMTI) has a Return-on-Tangible-Asset of 3.73% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Sanara MedTech and its competitors. According to the industry distribution chart, Sanara MedTech ranks #733 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 85.7%.
Is Sanara MedTech's Return-on-Tangible-Asset too high?
Sanara MedTech's current Return-on-Tangible-Asset is 3.73%. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.62. Sanara MedTech's value of 3.73% is 501.6% above this industry median. Based on the distribution chart, Sanara MedTech ranks #733 out of 855 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sanara MedTech has a GF Score™ of 74/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sanara MedTech's Return-on-Tangible-Asset compare to EMBC and KRMD?
According to the Medical Devices & Instruments industry distribution chart, Sanara MedTech ranks #733 out of 855 companies for Return-on-Tangible-Asset. This places Sanara MedTech in the lower half of its industry. The industry median Return-on-Tangible-Asset is 0.62. Sanara MedTech's value of 3.73% is 501.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.62, based on 855 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sanara MedTech's current Return-on-Tangible-Asset of 3.73% is 501.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Sanara MedTech and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sanara MedTech's current Return-on-Tangible-Asset is 3.73%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanara MedTech stock overvalued right now?
Based on GuruFocus' analysis, Sanara MedTech (SMTI) is currently considered Possible Value Trap. The stock's GF Value™ is $45.87, compared to a current price of $25.74 — trading 43.9% below its estimated fair value. The current Return-on-Tangible-Asset is 3.73% and 501.6% above the Medical Devices & Instruments industry median of 0.62. Sanara MedTech's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Sanara MedTech (SMTI), the current Return-on-Tangible-Asset is 3.73% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sanara MedTech (SMTI) Overvalued in 2026?
Based on GuruFocus' analysis, Sanara MedTech stock appears to be undervalued.
The current stock price of $25.74 is trading 43.9% below its estimated GF Value™ of $45.87.
GuruFocus considers Sanara MedTech to be Possible Value Trap.
Key valuation signals for SMTI:
Return-on-Tangible-Asset: 3.73%
GF Value™: $45.87 vs. price of $25.74 (43.9% below fair value)
Industry Position: 501.6% above the Medical Devices & Instruments median (#733 of 855)
No single metric tells the full story. See the SMTI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.
74GF Score
Get the complete analysis for SMTI
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SMTI has been successfully added to your 
